Open Access
Issue
Published:
28 May 2023
One-year survival in recipients older than 50 bridged to heart transplant with Impella 5.5 via axillary approach
)
Download citation
539
Views
39
Downloads
5
Crossref
3
WoS
3
Scopus
0
CSCD
Optimizing patients with advanced heart failure before orthotopic heart transplantation (OHT), especially in patients greater than 50 years old, is imperative to achieving successful post-transplant outcomes. Complications are well-described for patients bridged to transplant (BTT) with durable left ventricular assist device (LVAD) support. Given the lack of data available in older recipients after the recent increase in mechanical support use, we felt it crucial to report our center’s one-year outcomes in older recipients after heart transplantation with percutaneously placed Impella 5.5 as a BTT.
Forty-nine OHT patients were supported with the Impella 5.5 intended as a bridge between December 2019 and October 2022 at Mayo Clinic in Florida. Data were extracted from the electronic health record at baseline and during their transplant episode of care after Institutional Review Boards approval as exempt for retrospective data collection.
Thirty-eight patients aged 50 or older were supported with Impella 5.5 as BTT. Ten patients underwent heart and kidney transplantation within this cohort. The median age at OHT was 63 (58–68) years, with 32 male (84%) and six female patients (16%). Etiology was divided into ischemic (63%) and non-ischemic cardiomyopathy (37%). The baseline median ejection fraction was 19% (15–24). Most patients were in blood group O (60%), and 50% were diabetic. The average duration of support was 27 days (range 6–94). The median duration of follow-up is 488 days (185–693). For patients that have reached the 1-year follow-up timeframe (22 of 38, 58%), the 1-year post-transplant survival is 95%.
Our single-center data provides awareness for using the Impella 5.5 percutaneously placed axillary support device in older heart failure patients in cardiogenic shock as a bridge to transplantation. One-year survival outcomes after heart transplantation are excellent despite the older recipient’s age and prolonged pre-transplant support.
menu
One-year survival in recipients older than 50 bridged to heart transplant with Impella 5.5 via axillary approach
)
Abstract
Optimizing patients with advanced heart failure before orthotopic heart transplantation (OHT), especially in patients greater than 50 years old, is imperative to achieving successful post-transplant outcomes. Complications are well-described for patients bridged to transplant (BTT) with durable left ventricular assist device (LVAD) support. Given the lack of data available in older recipients after the recent increase in mechanical support use, we felt it crucial to report our center’s one-year outcomes in older recipients after heart transplantation with percutaneously placed Impella 5.5 as a BTT.
Forty-nine OHT patients were supported with the Impella 5.5 intended as a bridge between December 2019 and October 2022 at Mayo Clinic in Florida. Data were extracted from the electronic health record at baseline and during their transplant episode of care after Institutional Review Boards approval as exempt for retrospective data collection.
Thirty-eight patients aged 50 or older were supported with Impella 5.5 as BTT. Ten patients underwent heart and kidney transplantation within this cohort. The median age at OHT was 63 (58–68) years, with 32 male (84%) and six female patients (16%). Etiology was divided into ischemic (63%) and non-ischemic cardiomyopathy (37%). The baseline median ejection fraction was 19% (15–24). Most patients were in blood group O (60%), and 50% were diabetic. The average duration of support was 27 days (range 6–94). The median duration of follow-up is 488 days (185–693). For patients that have reached the 1-year follow-up timeframe (22 of 38, 58%), the 1-year post-transplant survival is 95%.
Our single-center data provides awareness for using the Impella 5.5 percutaneously placed axillary support device in older heart failure patients in cardiogenic shock as a bridge to transplantation. One-year survival outcomes after heart transplantation are excellent despite the older recipient’s age and prolonged pre-transplant support.
References(28)
JACC 2022 Source:Heidenreich P, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. J Am Coll Cardiol 2022; 79: e263−e421.
Kittleson MM, Shah P, Lala A, et al. INTERMACS profiles and outcomes of ambulatory advanced heart failure patients: A report from the REVIVAL Registry. J Heart Lung Transplant 2020; 39: 16−26.
Kilic A, Acker MA, Atluri P. Dealing with surgical left ventricular assist device complications. J Thorac Dis 2015; 7: 2158−2164.
Liu J, Yang BQ, Itoh A, et al. Impact of New UNOS allocation criteria on heart transplant practices and outcomes. Transplant Direct 2020; 7: e642.
Lala A, Rowland JC, Ferket BS, et al. Strategies of wait-listing for heart transplant vs durable mechanical circulatory support alone for patients with advanced heart failure. JAMA Cardiol 2020; 5: 652−659.
Borkon AM, Muehlebach GF, Jones PG, et al. An analysis of the effect of age on survival after heart transplant. J Heart Lung Transplant 1999; 18: 668−674.
Lloyd-Jones D, Adams R, Carnethon M, et al. Heart disease and stroke statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009; 119: 480−486.
Mozaffarian D, Benjamin EJ, Go AS. Heart disease and stroke statistics—2015 update: a report from the American Heart Association. Circulation 2015; 131: e29−e322.
Hertz MI, Taylor DO, Trulock EP, et al. The registry of the international society for heart and lung transplantation: nineteenth official report-2002. J Heart Lung Transplant 2002; 21: 950−970.
Miller, Leslie W. Listing criteria for cardiac transplantation: results of an American Society of Transplant Physicians-National Institutes of Health conference. Transplantation 1998; 66: 947−951.
Akintoye E, Alvarez P, Shin D, et al. Changing demographics, temporal trends in waitlist, and posttransplant outcomes after heart transplantation in the United States: Analysis of the UNOS Database 1991–2019. Circ Heart Fail 2021; 14: e008764.
Tjang YS, van der Heijden GJ, Tenderich G, et al. Impact of recipient’s age on heart transplantation outcome. Ann Thorac Surg 2008; 85: 2051−2055.
Siddiqi TJ, Minhas AMK, Greene SJ, et al. Trends in heart failure-related mortality among older adults in the United States From 1999-2019. JACC Heart Fail 2022; 10: 851−859.
Rushakoff JA, Kransdorf EP. Heart Transplant in Older Adults. Curr Transplant Rep 2022; 9: 48−54.
Jaiswal A, Gadela NV, Baran D, et al. Clinical outcomes of older adults listed for heart transplantation in the United States. J Am Geriatr Soc 2021; 69: 2507−2517.
Demers P, Moffatt S, Oyer PE, et al. Long-term results of heart transplantation in patients older than 60 years. J Thorac Cardiovasc Surg 2003; 126: 224−231.
Jang JM, Nativi J, Patel P, et al. REN3: percutaneous axillary temporary mechanical support improves renal function prior to heart transplantation in patients with chronic kidney disease. ASAIO J 2022; 68: 89.
Malkani S, Desai S, Ruiz J, et al. Risk of thrombocytopenia due to the interaction of systemic anticoagulation and impella purge solution in patients with temporary mechanical circulatory support. J Am Coll Cardiol 2023; 81(8_Supplement): 577.
O’Connell G, Wang AS, Kurlansky P, et al. Impact of UNOS allocation policy changes on utilization and outcomes of patients bridged to heart transplant with intra-aortic balloon pump. Clin Transplant 2022; 36: e14533.
Hanff TC, Harhay MO, Kimmel SE, et al. Trends in mechanical support use as a bridge to adult heart transplant under new allocation rules. JAMA Cardiol 2020; 5: 728−729.
Lam K, Sjauw KD, van der Meulen J, et al. A combined surgical and percutaneous approach through the axillary artery to introduce the Impella LP5.0 for short-term circulatory support. Int J Cardiol 2009; 134: 277−279.
Nishida H, Song T, Onsager D, et al. Significant vascular complications in percutaneous axillary intra-aortic balloon pump. Ann Vasc Surg 2022; 83: 42−52.
Malkani S, Ruiz J, Desai S, et al. Migration of intra-aortic balloon pump causing obstruction of the superior mesenteric artery. J Geriatr Cardiol 2022; 19: 928−929.
Haddad O, Jacob S, Ung RL, et al. Impella flow pump reinsertion after axillary graft thrombectomy: Technical points in replacing axillary Impella. SAGE Open Med Case Rep 2021; 9: 2050313X211032401.
FEEDBACK 
TOP